Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Advances in biomarker-directed therapies for gastric cancer

Michael Cecchini, Yale School of Medicine, New Haven, CT, reflects on the progress made in targeted therapies for gastric cancers (GC), recent advances in biomarker studies, and future directions for GC therapy. The development of immune checkpoint inhibitors has had a great impact in the field, beginning with the accelerated approval of pembrolizumab and now nivolumab in a first-line setting in combination with chemotherapy. There is more work needed to refine currently existing biomarkers such as PL1, CPS and HER2 to identify potential responders to targeted therapy. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.